Evidence map›Paper›PMID 23341972›Full record

ArticlePloS one2013

Involvement of EphB1 receptors signalling in models of inflammatory and neuropathic pain.

Vincent Cibert-Goton, Guanglu Yuan, Anna Battaglia, Sarah Fredriksson, Mark Henkemeyer, Thomas Sears, Isabella Gavazzi

Open access · goldAbstract read
In one paragraph

Article in PloS one, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 19 papers.

0numbers the graph read from it
0cells of the map it votes in
19citing papers in PubMed
1.7field-weighted citation impact, top 19% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

19 citing papers in PubMed, 38 citations in OpenAlex.

  1. Trial
  2. Article
  3. Article
  4. Article
  5. Contrastive learning in protein language space predicts interactions between drugs and protein targets.Proceedings of the National Academy of Sciences of the United States of America · 2023
    Article
  6. Review
  7. Identification of tetracycline combinations as EphB1 tyrosine kinase inhibitors for treatment of neuropathic pain.Proceedings of the National Academy of Sciences of the United States of America · 2021
    Article
  8. Article
  9. Review
  10. Article
  11. Article
  12. Article
  13. Review
  14. Article
  15. Article
  16. The Role of Ephs and Ephrins in Memory Formation.The international journal of neuropsychopharmacology · 2016
    Review
  17. Eph receptors and ephrins: therapeutic opportunities.Annual review of pharmacology and toxicology · 2015
    Review
  18. Article
  19. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 3 institutions in 2 countries.

Vincent Cibert-GotonWolfson Centre for Age-Related Diseases, The Wolfson Wing, King's College London, Guy's Campus, London, United Kingdom.
Guanglu Yuan
Anna Battaglia
Sarah Fredriksson
Mark Henkemeyer
Thomas Sears
Isabella Gavazzi
Wolfson Foundation · GBKing's College London · GBThe University of Texas Southwestern Medical Center · US

Funding

Bidirectional Tyrosine Kinase Signal TransductionR01MH066332 · NIMH · UT SOUTHWESTERN MEDICAL CENTER · PI HENKEMEYER, MARK J · 2002 to 2018
$6.1M
Biotechnology and Biological Sciences Research Council BB/C505816/1Biotechnology and Biological Sciences Research Council C505816NIMH NIH HHS 2R01 MH66332NIMH NIH HHS R01 MH066332Wellcome TrustWellcome Trust GR071663MA
6 · The paper itself

Abstract

EphB receptors tyrosine kinases and ephrinB ligands were first identified as guidance molecules involved in the establishment of topographical mapping and connectivity in the nervous system during development. Later in development and into adulthood their primary role would switch from guidance to activity-dependent modulation of synaptic efficacy. In sensory systems, they play a role in both the onset of inflammatory and neuropathic pain, and in the establishment of central sensitisation, an NMDA-mediated form of synaptic plasticity thought to underlie most forms of chronic pain. We studied wild type and EphB1 knockout mice in a range of inflammatory and neuropathic pain models to determine 1), whether EphB1 expression is necessary for the onset and/or maintenance of persistent pain, regardless of origin; 2), whether in these models cellular and molecular changes, e.g. phosphorylation of the NR2B subunit of the NMDA receptor, increased c-fos expression or microglial activation, associated with the onset of pain, are affected by the lack of functional EphB1 receptors. Differences in phenotype were examined behaviourally, anatomically, biochemically and electrophysiologically. Our results establish firstly, that functional EphB1 receptors are not essential for the development of normal nociception, thermal or mechanical sensitivity. Secondly, they demonstrate a widespread involvement of EphB1 receptors in chronic pain. NR2B phosphorylation, c-fos expression and microglial activation are all reduced in EphB1 knockout mice. This last finding is intriguing, since microglial activation is supposedly triggered directly by primary afferents, therefore it was not expected to be affected. Interestingly, in some models of long-term pain (days), mechanical and thermal hyperalgesia develop both in wild type and EphB1 knockout mice, but recovery is faster in the latter, indicating that in particular models these receptors are required for the maintenance, rather than the onset of, thermal and mechanical hypersensitivity. This potentially makes them an attractive target for analgesic strategies.

Indexed as

Signal TransductionAnimalsCarrageenanCell CountDisease Models, AnimalElectrophysiological PhenomenaFemaleFormaldehydeGene DeletionGene Expression RegulationGene Knockout TechniquesHyperalgesiaInflammationLocomotionMaleMiceCarrageenanFormaldehydeN-MethylaspartateProto-Oncogene Proteins c-fosReceptor, EphB1

Identifiers

PMID23341972
PMCPMC3547059
OpenAlexW2005901996

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.